XOMA Royalty Corp. (XOMA) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Current Price
$26.45
Price Target
$68.25
Target Range
$50.00 — $97.00
Analyst Rating
Buy
Forward P/E39.7x
Trailing P/E-16.0x
Forward PEG—
Implied Growth-37.5%
Median Target$63.00
Analyst Spread68.9%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$50
+89.0%
Consensus
$68
+158.0%
Bull Case
$97
+266.7%
XOMA Price Target Analysis
Updated March 5, 2026As of March 5, 2026, XOMA Royalty Corp. (XOMA) has a Wall Street consensus price target of $68.25, based on estimates from 10 covering analysts. With the stock currently trading at $26.45, this represents a potential upside of +158.0%. The company has a market capitalization of $316M.
Analyst price targets range from a low of $50.00 to a high of $97.00, representing a 69% spread in expectations. The median target of $63.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,4 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, XOMA trades at a trailing P/E of -16.0x and forward P/E of 39.7x. Analysts expect EPS to grow -37.5% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+93.8%
Avg Forward P/E24.9x
Peers with Coverage5 / 8
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
| XOMAXOMA Royalty Corp. | $316M | $26.45 | $68.25 | +158.0% | Buy | 39.7x | 10 |
 RPRXRoyalty Pharma plc | $26.8B | $47.43 | $49.40 | +4.2% | Buy | 9.8x | 11 |
 LGNDLigand Pharmaceuticals Incorporated | $4.1B | $208.95 | $248.00 | +18.7% | Buy | 24.6x | 16 |
 INVAInnoviva, Inc. | $1.7B | $22.73 | $32.50 | +43.0% | Buy | 11.5x | 10 |
 BTXBlackRock Technology and Private Equity Term Trust | $773M | $6.62 | — | — | — | — | — |
 XOMAPXOMA Corporation | $317M | $25.77 | — | — | Buy | 38.7x | 9 |
 CBUSCibus, Inc. | $99M | $3.33 | $11.50 | +245.3% | Buy | — | 3 |
 CDTCDT Equity Inc. | $1M | $0.71 | — | — | — | — | — |
Upside Potential Comparison
CBUSXOMAINVALGNDRPRXSee XOMA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs XOMA Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare XOMA vs LLY
See how XOMA stacks up against sector leader Eli Lilly and Company.
Start ComparisonFrequently Asked Questions
What is the XOMA stock price target for 2026?
The consensus Wall Street price target for XOMA is $68.25, representing 158.0% upside from the current price of $26.45. With 10 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is XOMA a buy, sell, or hold?
XOMA has a consensus rating of "Buy" based on 10 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $68.25 implies 158.0% upside from current levels.
Is XOMA stock overvalued or undervalued?
At a forward P/E of 39.7147x, XOMA trades at a premium valuation. The consensus price target of $68.25 (158.0% upside) suggests analysts still see growth justifying the multiple.
How high can XOMA stock go?
The most bullish Wall Street analyst has a price target of $97 for XOMA, while the most conservative target is $50. The consensus of $68.25 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover XOMA stock?
XOMA is moderately covered, with 10 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 4 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the XOMA stock forecast?
The 12-month XOMA stock forecast based on 10 Wall Street analysts shows a consensus price target of $68.25, with estimates ranging from $50 (bear case) to $97 (bull case). The median consensus rating is "Buy".
What is XOMA's forward P/E ratio?
XOMA trades at a forward P/E ratio of 39.7x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy XOMA stock?
Wall Street analysts are very optimistic on XOMA, with a "Buy" consensus rating and $68.25 price target (158.0% upside). 6 of 10 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do XOMA price targets vary so much?
XOMA analyst price targets range from $50 to $97, a 69% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $68.25 consensus represents the middle ground.